What Nonbiopharma Companies Could Have The Biggest Impact On The Industry In 2020?

Coming into the election cycle, the political environment may have a major impact on the biopharma industry in the near term. The capital markets have a difficulty operating in volatile times because of this uncertainty. This ambiguity in the near term could have a direct impact on the IPO market, for example.

Longer term, the true transformational change could come in the supply chain/distribution model. Amazon (and PillPack) may have the ambition and ability to change the dynamics of servicing the end customer — the patient. It’s conceivable that Amazon could be able to become a distributor/online pharmacy. Other organizations like NURX are developing an integrated tele-prescribing, adjudication, and dispensing model. NURX recently announced a $52 million Series C round lead by Kleiner Perkins.

AL ALTOMARI is chairman and CEO of Agile Therapeutics and a member of the company’s board of directors.